Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2021-02-16 4:53 pm Purchase |
2020-12-31 | 13G | BioCryst Pharmaceuticals, Inc. BCRX |
Baker Bros. Advisors LP | 18,178,881 9.990% |
2,303,756 (+14.51%) |
Filing History |
| 2021-02-16 4:30 pm Sale |
2020-12-31 | 13G | BioCryst Pharmaceuticals, Inc. BCRX |
Citadel Advisors LLC | 6,660,717 3.800% |
-2,234,718 (-25.12%) |
Filing History |
| 2021-02-16 3:16 pm Sale |
2020-12-31 | 13G | BioCryst Pharmaceuticals, Inc. BCRX |
Point72 Asset Management, L.P. | 3,691,632 2.100% |
-4,696,422 (-55.99%) |
Filing History |
| 2021-02-11 12:54 pm Sale |
2020-12-31 | 13G | BioCryst Pharmaceuticals, Inc. BCRX |
JANUS HENDERSON GROUP PLC JHG |
0 0.000% |
-9,408,481 (Position Closed) |
Filing History |
| 2021-02-10 4:28 pm Sale |
2020-12-31 | 13G | BioCryst Pharmaceuticals, Inc. BCRX |
Integrated Core Strategies (US) LLC | 286,632 0.200% |
-9,688,845 (-97.13%) |
Filing History |
| 2021-02-10 10:39 am Purchase |
2020-12-31 | 13G | BioCryst Pharmaceuticals, Inc. BCRX |
The Vanguard Group | 11,599,334 6.570% |
3,477,703 (+42.82%) |
Filing History |
| 2021-02-05 11:42 am Sale |
2020-12-31 | 13G | BioCryst Pharmaceuticals, Inc. BCRX |
STATE STREET CORP STT |
11,056,979 6.260% |
-6,896,891 (-38.41%) |
Filing History |
| 2021-01-28 5:56 pm Purchase |
2020-12-31 | 13G | BioCryst Pharmaceuticals, Inc. BCRX |
BLACKROCK INC BLK |
16,259,745 9.200% |
4,109,534 (+33.82%) |
Filing History |
| 2021-01-25 4:43 pm Purchase |
2021-01-15 | 13G | BioCryst Pharmaceuticals, Inc. BCRX |
Sarissa Capital Management LP | 8,844,000 5.000% |
8,844,000 (New Position) |
Filing History |
| 2020-12-10 07:14 am Purchase |
2020-11-30 | 13G | BioCryst Pharmaceuticals, Inc. BCRX |
STATE STREET CORP STT |
17,953,870 10.170% |
17,953,870 (New Position) |
Filing History |
| 2020-06-10 5:07 pm Purchase |
2020-06-01 | 13G | BioCryst Pharmaceuticals, Inc. BCRX |
Citadel Advisors LLC | 8,895,435 5.000% |
8,895,435 (New Position) |
Filing History |